Do Wegovy side effects get worse as the dose increases?

Why the titration schedule exists and what it means for your symptoms

The Wegovy dosing ladder (starting at 0.25 mg and climbing over several months toward the 2.4 mg maintenance dose) is not arbitrary. It is built around tolerability. Semaglutide slows gastric emptying and signals fullness through GLP-1 receptors in the gut and brain, and that dual action is precisely why nausea and digestive disruption are so common early on. Each time the weekly dose rises, the body is effectively recalibrating, and that recalibration has a symptom cost for many people.

The practical upshot: if you felt fine at 0.5 mg but unsettled at 1.0 mg, that is expected pharmacology rather than a sign something has gone wrong. The full Wegovy dosing schedule explains what each rung involves. Most people find that by the time the next increase is due, the previous dose has become comfortable, and that pattern tends to repeat. What does not usually happen is a steady worsening of symptoms throughout treatment at a stable dose; persistence past a couple of weeks at the same dose warrants a conversation with your prescriber.

The higher doses (1.7 mg and 2.4 mg) carry a somewhat greater chance of GI symptoms than the starting doses, reflecting the stronger effect on gastric motility. If you want to understand what side effects to expect each time your semaglutide dose increases, that page walks through what typically changes at each rung. Research published in the STEP 1 trial in the New England Journal of Medicine reported that gastrointestinal events were the most common reason participants stopped treatment, though the majority stayed the course. That context matters: side effects are real, dose-related, and manageable for most people, but not trivial.

The decision most people face: push through or pause the titration

This is the real choice that brings many people to search this question. You are due to increase your dose, your last step was uncomfortable, and you are weighing up whether to go ahead. It is a reasonable thing to be uncertain about. The answer is not one-size-fits-all, and it belongs in a clinical conversation rather than a general article.

What the evidence does support: slowing the titration (staying at a lower dose for longer before stepping up) is a recognised strategy for managing side effects without stopping treatment. The prescriber's job is to make that call with your specific history in mind, not to apply a rigid timetable. If nausea was severe at the 1.7 mg step, that is exactly the kind of information a prescriber needs before authorising the next increase.

Practical things that tend to help at any dose step: eating smaller meals, choosing lower-fat foods, staying well hydrated, and avoiding lying down immediately after eating. These are consistent with NHS guidance and with what our prescribers discuss during aftercare. They are supportive measures, not substitutes for clinical review if symptoms are severe.

Anyone who has recently moved up to the intermediate stage can find out more about what treatment at the 1.25 mg dose involves as part of understanding where they are in the schedule.

When to get medical help, and the effects that are not dose-adjustment discomfort

Most side effects from stepping up the dose are unpleasant but not dangerous. A few are different, and they matter.

Get urgent medical help if you develop severe, persistent abdominal pain, particularly if it radiates toward your back and may come with vomiting. This presentation can indicate acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonists specifically flagging acute pancreatitis as an infrequent but serious risk, it is not something to wait out at home.

Other symptoms that need prompt attention: signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing), severe dehydration following prolonged vomiting or diarrhoea, and gallbladder symptoms such as sudden right-sided or upper abdominal pain with fever. If you experience a rapid or unexplained change in mood, or thoughts of self-harm, contact a healthcare professional that day.

For anything that does not feel right but is not an emergency, your first call should be your prescriber or the aftercare support provided by whoever supplies your treatment. At nume (sorry, at our pharmacy) that means seven-day prescriber access, not a waiting queue. People sometimes ask whether a side effect is from the dose or something else; a prescriber can usually tell. You can also report anything unexpected directly to the MHRA via the Yellow Card scheme, and patients are actively encouraged to do so.

What the 2.4 mg dose looks like in practice

For people who reach the full 2.4 mg maintenance dose, the picture shifts. You are no longer in titration; the body has adjusted to semaglutide's presence. Many people find side effects at maintenance are considerably milder than at intermediate steps, because there is no further increase to trigger recalibration. The side-effect profile at 2.4 mg is worth reading in full if you are approaching that stage.

The pen that arrives from a GPhC-registered pharmacy (tracked by DPD, in plain unmarked packaging) contains four pre-set weekly doses. Nothing about the pen format changes with the dose: same injector design, same injection sites (abdomen, thigh, or upper arm), same once-weekly rhythm. What changes is the concentration of semaglutide inside it, and with that, the strength of effect on appetite, gastric emptying, and (during a step-up period) the likelihood of temporary GI disruption.

If the 7.2 mg higher-maintenance dose becomes relevant to your treatment, that is a prescriber-led decision based on your response at 2.4 mg; the titration process for reaching it follows the same principle of gradual increase. The weight loss treatments page sets out the full range of options our clinical team can assess you for.